Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures <i>NPM1/FLT3</i>-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model

• Bing Z. Carter,
• Po Yee Mak,
• Wenjing Tao,
• Lauren B. Ostermann,
• Duncan H. Mak,
• Baozhen Ke,
• Peter Ordentlich,
• Gerard M. McGeehan,
• Michael Andreeff

Affiliations

Bing Z. Carter

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Po Yee Mak

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Wenjing Tao

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Lauren B. Ostermann

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Duncan H. Mak

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Baozhen Ke

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Peter Ordentlich

Syndax, Waltham, MA

Gerard M. McGeehan

Syndax, Waltham, MA

Michael Andreeff

Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX